CN85102921B - 制备具有药物作用的透明质酸组份及含该组份的药物的方法 - Google Patents

制备具有药物作用的透明质酸组份及含该组份的药物的方法 Download PDF

Info

Publication number
CN85102921B
CN85102921B CN85102921A CN85102921A CN85102921B CN 85102921 B CN85102921 B CN 85102921B CN 85102921 A CN85102921 A CN 85102921A CN 85102921 A CN85102921 A CN 85102921A CN 85102921 B CN85102921 B CN 85102921B
Authority
CN
China
Prior art keywords
hyaluronic acid
molecular weight
component
film
hyaluronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CN85102921A
Other languages
English (en)
Chinese (zh)
Other versions
CN85102921A (zh
Inventor
弗朗西斯科·戴拉·瓦莱
西尔瓦娜·洛伦兹
奥里略·罗密欧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia SA
Original Assignee
Fidia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN85102921(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to IT8547924A priority Critical patent/IT1229075B/it
Application filed by Fidia SA filed Critical Fidia SA
Priority to CN85102921A priority patent/CN85102921B/zh
Priority claimed from IT48980/85A external-priority patent/IT1184675B/it
Priority to IL78263A priority patent/IL78263A0/xx
Priority to AT86302291T priority patent/ATE98495T1/de
Priority to IE84786A priority patent/IE64440B1/en
Priority to DE3689384T priority patent/DE3689384T3/de
Priority to IN248/CAL/86A priority patent/IN165867B/en
Priority to EP86302291A priority patent/EP0197718B2/en
Priority to EP19930200175 priority patent/EP0555898A3/en
Priority to PH33597A priority patent/PH29979A/en
Priority to FR868604601A priority patent/FR2579895B1/fr
Priority to FI861395A priority patent/FI83966C/fi
Priority to DK149886A priority patent/DK149886A/da
Priority to AR86303552A priority patent/AR245369A1/es
Priority to LU86386A priority patent/LU86386A1/fr
Priority to ZA862463A priority patent/ZA862463B/xx
Priority to HU861402A priority patent/HU204202B/hu
Priority to US06/847,632 priority patent/US4736024A/en
Priority to BE1/011467A priority patent/BE904547A/fr
Priority to AU55662/86A priority patent/AU592077B2/en
Priority to ES553714A priority patent/ES8800055A1/es
Priority to CA000617080A priority patent/CA1341087C/en
Priority to NO861331A priority patent/NO174277C/no
Priority to KR1019860002595A priority patent/KR910006810B1/ko
Priority to CH1340/86A priority patent/CH672886A5/fr
Priority to CA000617112A priority patent/CA1341418C/en
Priority to PT82342A priority patent/PT82342B/pt
Priority to CA000505909A priority patent/CA1340825C/en
Priority to JP61079060A priority patent/JP2585216B2/ja
Publication of CN85102921A publication Critical patent/CN85102921A/zh
Priority to NZ215676A priority patent/NZ215676A/xx
Publication of CN85102921B publication Critical patent/CN85102921B/zh
Priority to IN155/CAL/89A priority patent/IN169540B/en
Priority to US07/452,681 priority patent/US5166331A/en
Priority to US07/931,949 priority patent/US5442053A/en
Priority to IL106094A priority patent/IL106094A0/xx
Priority to US08/426,905 priority patent/US5631241A/en
Priority to JP8151346A priority patent/JP2677778B2/ja
Expired legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN85102921A 1982-09-28 1985-04-09 制备具有药物作用的透明质酸组份及含该组份的药物的方法 Expired CN85102921B (zh)

Priority Applications (36)

Application Number Priority Date Filing Date Title
IT8547924A IT1229075B (it) 1985-04-05 1985-04-05 Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
CN85102921A CN85102921B (zh) 1985-04-05 1985-04-09 制备具有药物作用的透明质酸组份及含该组份的药物的方法
IL78263A IL78263A0 (en) 1985-04-05 1986-03-25 New medicaments for topical use comprising hyaluronic acid and its derivatives
AT86302291T ATE98495T1 (de) 1985-04-05 1986-03-27 Arzneimittel zur topischen anwendung.
IE84786A IE64440B1 (en) 1985-04-05 1986-03-27 New medicaments for topical use
DE3689384T DE3689384T3 (de) 1985-04-05 1986-03-27 Arzneimittel zur örtlichen Anwendung
IN248/CAL/86A IN165867B (enExample) 1985-04-05 1986-03-27
EP86302291A EP0197718B2 (en) 1985-04-05 1986-03-27 New medicaments for topical use
EP19930200175 EP0555898A3 (en) 1985-04-05 1986-03-27 Medicaments for non-topical use
PH33597A PH29979A (en) 1985-04-05 1986-03-31 New medicaments for topical use
FI861395A FI83966C (fi) 1985-04-05 1986-04-01 Foerfarande foer framstaellning av farmaceutiskt aktiva hyaluronsyrasalter.
FR868604601A FR2579895B1 (enExample) 1985-04-05 1986-04-01
DK149886A DK149886A (da) 1985-04-05 1986-04-02 Topiske medikamenter
AR86303552A AR245369A1 (es) 1985-04-05 1986-04-03 Procedimiento para la fabricacion de una sal del acido hialuronico.
LU86386A LU86386A1 (fr) 1985-04-05 1986-04-03 Nouveaux medicaments a usage topique
ZA862463A ZA862463B (en) 1985-04-05 1986-04-03 New medicaments for topical use
HU861402A HU204202B (en) 1985-04-05 1986-04-03 Process for producing new, local pharmaceutical compositions
US06/847,632 US4736024A (en) 1985-04-05 1986-04-03 Process for preparing salt of hyaluronic acid with a pharmaceutically active substance
BE1/011467A BE904547A (fr) 1985-04-05 1986-04-03 Nouveaux medicaments a usage topique.
AU55662/86A AU592077B2 (en) 1985-04-05 1986-04-04 Hydralonic acid compositions
CA000505909A CA1340825C (en) 1985-04-05 1986-04-04 Hyaluronic acid fraction for use as a drug delivery system for medicaments
JP61079060A JP2585216B2 (ja) 1985-04-05 1986-04-04 新規医薬組成物
PT82342A PT82342B (pt) 1985-04-05 1986-04-04 Processo para a preparacao de derivados do acido hialuronico
ES553714A ES8800055A1 (es) 1985-04-05 1986-04-04 Procedimiento para la preparacion de una composicion que contiene una sal de acido hialuronico.
CA000617080A CA1341087C (en) 1983-07-13 1986-04-04 Medicaments including hyaluronic acid as a drug delivery system
NO861331A NO174277C (no) 1985-04-05 1986-04-04 Fremgangsmåte for fremstilling av et hyaluronsyresalt
KR1019860002595A KR910006810B1 (ko) 1985-04-05 1986-04-04 신규한 히알루론산염의 제조방법
CH1340/86A CH672886A5 (enExample) 1985-04-05 1986-04-04
CA000617112A CA1341418C (en) 1985-04-05 1986-04-04 Substantially-pure non-inflammatory hyaluronic acid
NZ215676A NZ215676A (en) 1985-04-05 1988-04-02 Topical pharmaceutical compositions with vehicle containing hyaluronic acid derivatives; preparation or hyaluronic acid salts
IN155/CAL/89A IN169540B (enExample) 1985-04-05 1989-02-23
US07/452,681 US5166331A (en) 1983-10-10 1989-12-19 Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US07/931,949 US5442053A (en) 1982-09-28 1992-08-19 Salts and mixtures of hyaluronic acid with pharmaceutically active substances, pharmaceutical compositions containing the same and methods for administration of such compositions
IL106094A IL106094A0 (en) 1985-04-05 1993-06-22 Salts of hyaluronic acid
US08/426,905 US5631241A (en) 1983-10-10 1995-04-21 Pharmaceutical compositions containing hyaluronic acid fractions
JP8151346A JP2677778B2 (ja) 1985-04-05 1996-06-12 新規医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT8547924A IT1229075B (it) 1985-04-05 1985-04-05 Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
CN85102921A CN85102921B (zh) 1985-04-05 1985-04-09 制备具有药物作用的透明质酸组份及含该组份的药物的方法
IT48980/85A IT1184675B (it) 1985-12-23 1985-12-23 Procedimento per la preparazione di sali dell'acido ialuronico

Publications (2)

Publication Number Publication Date
CN85102921A CN85102921A (zh) 1986-10-08
CN85102921B true CN85102921B (zh) 1988-06-08

Family

ID=36694284

Family Applications (1)

Application Number Title Priority Date Filing Date
CN85102921A Expired CN85102921B (zh) 1982-09-28 1985-04-09 制备具有药物作用的透明质酸组份及含该组份的药物的方法

Country Status (27)

Country Link
US (1) US4736024A (enExample)
EP (2) EP0555898A3 (enExample)
JP (2) JP2585216B2 (enExample)
KR (1) KR910006810B1 (enExample)
CN (1) CN85102921B (enExample)
AR (1) AR245369A1 (enExample)
AT (1) ATE98495T1 (enExample)
AU (1) AU592077B2 (enExample)
BE (1) BE904547A (enExample)
CA (2) CA1341418C (enExample)
CH (1) CH672886A5 (enExample)
DE (1) DE3689384T3 (enExample)
DK (1) DK149886A (enExample)
ES (1) ES8800055A1 (enExample)
FI (1) FI83966C (enExample)
FR (1) FR2579895B1 (enExample)
HU (1) HU204202B (enExample)
IE (1) IE64440B1 (enExample)
IL (1) IL78263A0 (enExample)
IN (1) IN165867B (enExample)
IT (1) IT1229075B (enExample)
LU (1) LU86386A1 (enExample)
NO (1) NO174277C (enExample)
NZ (1) NZ215676A (enExample)
PH (1) PH29979A (enExample)
PT (1) PT82342B (enExample)
ZA (1) ZA862463B (enExample)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1186772B (it) * 1985-10-10 1987-12-16 Crinos Industria Farmaco Composto ad attivita' pilostimolante
CA1291123C (en) * 1986-03-14 1991-10-22 Abraham Nimrod Heavy metal salts of hyaluronic acid useful as antimicrobial agents
US5668116A (en) * 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
WO1988007060A1 (en) * 1987-03-19 1988-09-22 Arthropharm Pty. Limited Anti-inflammatory compounds and compositions
ATE66133T1 (de) * 1987-05-20 1991-08-15 Ueno Seiyaku Oyo Kenkyujo Kk Kondom.
DE3883645T2 (de) * 1987-07-01 1994-02-03 Genentech Inc Therapeutische Zusamensetzungen und Verfahren zur Verhinderung von Fibrinablagerung und Adhäsionen.
US5055298A (en) * 1987-12-01 1991-10-08 Chemisches Laboratorium Dr. Kurt Richter Gmbh Cosmetic composition comprising an extracellular connective tissue matrix
JPH01213227A (ja) * 1988-02-23 1989-08-28 Tadashi Koyake 軟膏剤及び液剤
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US4981955A (en) * 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
JPH0232013A (ja) * 1988-07-20 1990-02-01 Denki Kagaku Kogyo Kk 点鼻剤
JPH02200624A (ja) * 1989-01-30 1990-08-08 Nippon Kayaku Co Ltd 歯科用包帯剤
US6458774B1 (en) * 1989-02-24 2002-10-01 Richter Gedeon Vegyeszeti Gyar Rt. Compositions containing hyaluronic acid associates and a process for preparing same
US5472950A (en) * 1989-02-24 1995-12-05 Richter Gedeon Vegyeszeti Gyar Rt. Compositions containing cobalt hyaluronic acid complex
HU203372B (en) 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
JP2945993B2 (ja) * 1989-12-05 1999-09-06 武田薬品工業株式会社 外用剤
US5141928B1 (en) * 1989-12-20 1995-11-14 Brujo Inc Ophthalmic medication
NL8903155A (nl) * 1989-12-23 1991-07-16 Stamicarbon Harssamenstelling op basis van een polyesterhars, een aminohars en een epoxyhars.
ES2146200T3 (es) * 1990-02-13 2000-08-01 Ethicon Inc Medicamentos inducidos peritonealmente.
IT1240316B (it) * 1990-02-21 1993-12-07 Ricerca Di Schiena Del Dr. Michele G. Di Schiema & C. Composizioni a base di acido ialuronico ad alto peso molecolare somministrabili per via topica per il trattamento di infiammazioni del cavo orale ,per la cosmetica e l'igiene del cavo orale
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
IT1243435B (it) * 1990-10-05 1994-06-10 Altergon Sa Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti
US5492936A (en) * 1990-11-30 1996-02-20 Allergan, Inc. Bimodal molecular weight hyaluronate formulations and methods for using same
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US5834444A (en) * 1991-07-03 1998-11-10 Hyal Pharmaceutical Corporation Hyaluronic acid and salts thereof inhibit arterial restenosis
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5990095A (en) 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
DE69333005T2 (de) * 1992-02-10 2004-04-01 Advanced Medical Optics, Inc., Santa Ana Zusammensetzungen von hyaluronat mit bimodalem molekulargewicht und verfahren zu deren verwendung
US6147059A (en) * 1992-02-20 2000-11-14 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
CA2130762C (en) * 1994-08-24 1999-07-06 Eva Anne Turley Treatment of disease and conditions associated with macrophage infiltration
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
IT1263144B (it) * 1993-02-04 1996-08-01 Lanfranco Callegaro Composizioni farmaceutiche comprendenti materiale spugnoso costituito da derivati esterei dell'acido ialuronico in associazione con altre sostanze farmacologicamente attive
AU5643994A (en) * 1993-03-04 1994-09-08 Genzyme Limited Controlled molecular weight reduction of polymers
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
JP4010574B2 (ja) * 1994-12-05 2007-11-21 電気化学工業株式会社 皮膚外用剤
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
IT1287227B1 (it) * 1996-04-04 1998-08-04 Fidia Spa In Amministrazione S Acido ialuronico quale componente del liquido di conservazione della cornea
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US6451326B2 (en) 1996-05-02 2002-09-17 Burt D. Ensley Cosmetic compositions
HU225991B1 (en) * 1997-04-29 2008-02-28 Richter Gedeon Nyrt Use of the zinc hyaluronate associate (complex) for the preparation of pharmaceutical compositions for oral use against peptic ulcer
IT1287967B1 (it) * 1996-10-17 1998-09-10 Fidia Spa In Amministrazione S Preparazioni farmaceutiche per uso anestetico locale
US5843186A (en) * 1996-12-20 1998-12-01 Implemed, Inc. Intraocular lens with antimicrobial activity
US5789571A (en) * 1997-01-15 1998-08-04 Biocoat Incorporated Method of making free acids from polysaccharide salts
US20050090662A1 (en) * 1997-01-15 2005-04-28 Beavers Ellington M. Method of making free acids from polysaccharide salts
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
AU738788B2 (en) * 1997-04-04 2001-09-27 Fidia Farmaceutici S.P.A. N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation
US6123957A (en) * 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
DE69833665T2 (de) * 1997-08-08 2006-11-09 Duke University Zusammensetzungen zur vereinfachung von chirurgischen verfahren
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
JP2002193830A (ja) * 1998-10-19 2002-07-10 High Chem Co Ltd 経鼻投与用医薬製剤
DK172900B1 (da) * 1998-12-18 1999-09-27 Per Julius Nielsen Præparat samt kit til brug ved intraoculære operationer
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
DK1140198T3 (da) 1999-01-13 2008-03-10 Alchemia Oncology Pty Ltd Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
WO2000044367A2 (en) * 1999-02-01 2000-08-03 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
WO2001091796A2 (en) 2000-06-01 2001-12-06 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US6828308B2 (en) * 2000-07-28 2004-12-07 Sinclair Pharmaceuticals, Ltd. Compositions and methods for the treatment or prevention of inflammation
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
ITMI20010708A1 (it) * 2001-04-03 2002-10-03 Alessandro Randazzo Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
WO2003018062A1 (en) * 2001-08-27 2003-03-06 Meditech Research Limited Improved therapeutic protocols
ES2282469T3 (es) * 2001-09-19 2007-10-16 Nycomed Gmbh Combinacion de un nsaid y un inhibidor de pde-4.
ITMI20021666A1 (it) 2002-07-26 2004-01-26 Jasper Ltd Liability Co Derivati dell'acido ialuronico
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
WO2005016386A1 (en) * 2003-08-19 2005-02-24 Meditech Research Limited Improved therapeutic protocols
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US7625581B2 (en) * 2003-12-19 2009-12-01 Ethicon, Inc. Tissue scaffolds for use in muscoloskeletal repairs
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
FR2865651B1 (fr) 2004-01-29 2007-09-28 Fabre Pierre Dermo Cosmetique Compositions topiques associant des fragments de hyaluronate de sodium et un retinoide utiles en dermatologie cosmetique et medicale
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
GB0416397D0 (en) * 2004-07-22 2004-08-25 Glaxo Group Ltd Pharmaceutical formulations
SE0402272D0 (sv) 2004-09-21 2004-09-21 Amo Groningen Bv Methods of treating a body site with a viscoelastic preparation
CA2580890C (en) * 2004-09-21 2013-10-22 Thom Terwee Viscoelastic solution or gel formulation, and methods of treating a body site with the same
EP1721602A1 (en) * 2005-05-11 2006-11-15 The Jordanian Pharmaceutical Manufacturing Co. Controlled release oral drug delivery system
FR2888752B1 (fr) * 2005-07-22 2007-10-05 Fabre Pierre Dermo Cosmetique Complexe d'association intermoleculaire d'un transporteur et d'un principe actif
WO2007012133A1 (en) * 2005-07-27 2007-02-01 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
MY149606A (en) * 2005-09-07 2013-09-13 Alchemia Oncology Pty Ltd Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2007038252A2 (en) * 2005-09-22 2007-04-05 Key Douglas J Methods and compositions for treating skin lines and wrinkles and improving skin quality
WO2010132402A1 (en) * 2009-05-11 2010-11-18 Morria Biopharmaceuticals, Inc Lipid-polymer conjugates, their preparation and uses thereof
JP4555232B2 (ja) * 2006-01-25 2010-09-29 Ｈｏｙａ株式会社 組織の蛍光染色方法
US8668676B2 (en) 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
CA2654255A1 (en) * 2006-06-28 2008-01-03 Novozymes Biopolymer A/S Compositions with several hyaluronic acid fractions for cosmetic and medical uses
WO2008003321A2 (en) * 2006-07-07 2008-01-10 Novozymes Biopolymer A/S Compositions with several hyaluronic acid fractions for cosmetic use
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
AU2007295894B2 (en) 2006-09-13 2013-10-17 Enhance Skin Products, Inc. Cosmetic composition for the treatment of skin and methods thereof
AU2008210557B2 (en) 2007-01-30 2013-08-01 Cypress Pharmaceutical, Inc. Hyaluronate compositions
US20090068122A1 (en) * 2007-09-06 2009-03-12 Shira Pilch Dentifrice Compositions for Treating Xerostomia
BRPI0819075A2 (pt) 2007-11-16 2014-10-07 Vicept Therapeutics Inc Método para tratar púrpura em um indivíduo e método para diminuir a púrpura em um indivíduo antes de um procedimento cirúrgico
KR20110017365A (ko) * 2008-05-30 2011-02-21 페어필드 클리니컬 트라이얼즈 엘엘씨 피부 염증 및 변색을 위한 방법 및 조성물
WO2010003797A1 (en) * 2008-07-09 2010-01-14 Novozymes Biopharma Dk A/S Hyaluronic acid for corneal wound healing
MX2011003557A (es) 2008-10-02 2011-09-01 Lrr & D Ltd Vendas para heridas con capa de interfaz.
CN101385874B (zh) * 2008-10-23 2012-11-28 武汉大学 一种含有高分子透明质酸的生物滑液的制备方法
US8545554B2 (en) 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
TWI383796B (zh) 2009-08-14 2013-02-01 Holy Stone Healthcare Co Ltd Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer
TWI516269B (zh) 2009-08-14 2016-01-11 禾伸堂生技股份有限公司 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US9029347B2 (en) 2010-08-05 2015-05-12 Holy Stone Healthcare Co., Ltd. Method and mixture for treating and preventing inflammatory bowel disease
IT1407283B1 (it) * 2010-12-06 2014-04-04 Paoli Ambrosi De Nuovo composto di carnosina
CZ303548B6 (cs) 2011-01-05 2012-11-28 Contipro Pharma A.S. Zdravotní prípravek tvorící jód, zpusob jeho prípravy a bandáž, která jej obsahuje
CZ22394U1 (cs) 2011-03-11 2011-06-20 Contipro C, A.S. Antimikrobiální smes a kryt pro podporu hojení ran s antimikrobiálním úcinkem
LT2543357T (lt) 2011-07-07 2018-06-11 Holy Stone Healthcare Co.,Ltd. Kompozicija, skirta panaudoti su uždegimu susijusių susirgimų gydymui arba prevencijai
ES2665254T3 (es) 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
ITMI20111747A1 (it) 2011-09-28 2013-03-29 Fidia Farmaceutici Composizioni farmaceutiche topiche comprendenti aciclovir
ITPD20120173A1 (it) 2012-05-31 2013-12-01 Fidia Farmaceutici "nuovo sistema di rilascio di proteine idrofobiche"
JP2014141475A (ja) * 2012-12-27 2014-08-07 Daiichi Sankyo Co Ltd 新規美白剤
KR101412776B1 (ko) 2013-03-11 2014-07-01 가톨릭대학교 산학협력단 각결막염 치료용 점안제 조성물 및 이의 제조 방법
CN103319627A (zh) * 2013-07-10 2013-09-25 南宁中诺生物工程有限责任公司 一种对透明质酸钠进行分子量分级的方法
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
JP2017505805A (ja) * 2014-02-11 2017-02-23 オラシス ファーマシューティカルズ リミティド 老眼矯正に使用される眼科用薬理組成物及びその投与
EP2910255A1 (en) * 2014-02-19 2015-08-26 MedSkin Solutions Dr. Suwelack AG Methods for the production of biopolymers with defined average molecular weight
US9603867B2 (en) * 2015-03-03 2017-03-28 Yung Shin Pharm. Ind. Co., Ltd. Pharmaceutical composition for improving wound healing or prophylactically preventing or inhibiting scar formation
ITUB20152542A1 (it) * 2015-07-28 2017-01-28 Altergon Sa Formulati oftalmici a base di complessi cooperativi di acido ialuronico a basso e alto peso molecolare
EP3415586B1 (en) 2016-02-12 2022-11-30 Laimu Corporation Wound treatment agent and method for producing same
JP7297308B2 (ja) 2016-08-19 2023-06-26 オラシス ファーマシューティカルズ リミティド 眼科用医薬組成物及びそれに関する使用
CN106727246A (zh) * 2017-02-08 2017-05-31 上海元茵生物科技有限公司 小牛血清细胞营养液
CN107802597B (zh) * 2017-12-08 2020-07-31 北京诺康达医药科技股份有限公司 一种玻璃酸钠组合物及其制备方法和应用
JP7309729B2 (ja) * 2018-01-18 2023-07-18 ファエス・ファルマ・ソシエダッド・アノニマ ビラスチン、β－シクロデキストリンおよび少なくとも１種のゲル化剤を含有する眼科用組成物
FR3086865B1 (fr) * 2018-10-04 2023-04-28 Matthieu Leconte Preparation ophtalmique et lentille d'orthokeratologie pour l'inhibition, la prevention et/ou la limitation de la progression de la myopie
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
IT201800010415A1 (it) * 2018-11-19 2020-05-19 Innate S R L Composizione iniettabile comprendente acido ialuronico e trealosio e uso della detta composizione.
EP4433053A4 (en) 2021-11-17 2025-09-17 Lenz Therapeutics Operations Inc ACECLIDINE DERIVATIVES, THEIR COMPOSITIONS AND METHODS OF USE
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583096A (en) * 1949-01-15 1952-01-22 Searle & Co Process for the production of high viscosity hyaluronic acid
DE1047380B (de) * 1954-08-18 1958-12-24 American Home Prod Verfahren zur Herstellung einer hyaluronidasefreien, teilweise depolymerisierte Hyaluronsaeure enthaltenden waessrigen Traegerloesung fuer Arzneimittel
GB818336A (en) * 1956-06-22 1959-08-12 Erba Carlo Spa A new acid aminopolysaccharide and a process for the production thereof
FR1425265A (fr) * 1962-05-14 1966-01-24 Parke Davis & Co Procédé de préparation d'un nouveau polysaccharide et de ses sels
FR3715M (fr) * 1964-06-11 1965-11-29 Lucien Nouvel Antithermiques et antirhumatismaux améliorés.
US3887703A (en) * 1967-03-24 1975-06-03 Oreal Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions
US3792164A (en) * 1970-03-31 1974-02-12 Chemway Corp Ophthalmic composition comprising water-soluble alkaloid salts of polyuronic acids
GB1283892A (en) * 1970-06-08 1972-08-02 Irwin Irville Lubowe Improvements in and relating to medicinal compositions for application to the skin and/or hair
DE2364373A1 (de) * 1973-12-22 1975-07-10 Hahn Carl Dr Gmbh Pharmazeutische und kosmetische praeparate zur aeusserlichen anwendung
US3936081A (en) * 1974-02-27 1976-02-03 R & G Sloane Manufacturing Co., Inc. Pipe joint and method of making same
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
HU172937B (hu) * 1975-12-18 1979-01-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh khondroitin-sernoj kisloty s mestno anestezirujuhhim ehffektom
SE7901565L (sv) * 1979-02-21 1980-08-22 Pharmacia Ab Medel for immunisering
JPS55153711A (en) * 1979-05-19 1980-11-29 Pola Chem Ind Inc Cosmetic lotion
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
JPS57183707A (en) * 1981-05-02 1982-11-12 Shiseido Co Ltd Cosmetic
US4359458A (en) * 1981-09-28 1982-11-16 American Cyanamid Company O-β. -D (and O-α.. -D) Multigalactopyranosyl, xylopyranosyl and glucopyranosyl sulfate salts
JPS591405A (ja) * 1982-06-28 1984-01-06 Shiseido Co Ltd 乳化組成物
JPS597106A (ja) * 1982-07-06 1984-01-14 Shiseido Co Ltd 乳化組成物
JPS5920212A (ja) * 1982-07-27 1984-02-01 Shiseido Co Ltd 乳化組成物
JPS5939338A (ja) * 1982-08-30 1984-03-03 Shiseido Co Ltd 乳化組成物
IT1212892B (it) * 1983-10-11 1989-11-30 Della Valle Francesco Acido ialuronico ottenuto per mezzodi filtrazione molecolare sprovvisto di attivita' infiammatoria e sua utilizzazione terapeutica
JPS59219209A (ja) * 1983-05-28 1984-12-10 Kanebo Ltd 皮膚化粧料
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
EP0138752B1 (de) * 1983-08-12 1986-11-12 Ciba-Geigy Ag Monokline Bleichromatpigmente
DE3334595A1 (de) * 1983-09-24 1985-04-18 B. Braun Melsungen Ag, 3508 Melsungen Wirkstoffdepot
FR2553099B1 (fr) * 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
JPS61180723A (ja) * 1985-02-06 1986-08-13 Sanwa Kagaku Kenkyusho:Kk 易吸収性カリジノゲナ−ゼ製剤用組成物
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
ES2146200T3 (es) * 1990-02-13 2000-08-01 Ethicon Inc Medicamentos inducidos peritonealmente.

Also Published As

Publication number Publication date
EP0197718B1 (en) 1993-12-15
KR910006810B1 (ko) 1991-09-02
NO861331L (no) 1986-10-06
JPS61236732A (ja) 1986-10-22
DE3689384T2 (de) 1994-07-07
BE904547A (fr) 1986-10-03
AR245369A1 (es) 1994-01-31
CH672886A5 (enExample) 1990-01-15
JP2585216B2 (ja) 1997-02-26
HU204202B (en) 1991-12-30
US4736024A (en) 1988-04-05
HUT40579A (en) 1987-01-28
JP2677778B2 (ja) 1997-11-17
DK149886A (da) 1986-10-06
EP0555898A3 (en) 1993-10-20
CA1341418C (en) 2003-01-21
ATE98495T1 (de) 1994-01-15
CN85102921A (zh) 1986-10-08
JPH09169667A (ja) 1997-06-30
IL78263A0 (en) 1986-07-31
NZ215676A (en) 1989-08-29
AU592077B2 (en) 1990-01-04
FI83966C (fi) 1991-09-25
NO174277B (no) 1994-01-03
EP0197718B2 (en) 2001-07-25
ES553714A0 (es) 1987-11-16
IT8547924A0 (it) 1985-04-05
ES8800055A1 (es) 1987-11-16
AU5566286A (en) 1986-10-16
IN165867B (enExample) 1990-02-03
IE64440B1 (en) 1995-08-09
LU86386A1 (fr) 1986-09-02
DK149886D0 (da) 1986-04-02
ZA862463B (en) 1987-12-30
IT1229075B (it) 1991-07-17
NO174277C (no) 1994-04-13
EP0555898A2 (en) 1993-08-18
EP0197718A3 (en) 1987-09-09
FR2579895B1 (enExample) 1990-11-23
DE3689384D1 (de) 1994-01-27
PT82342B (pt) 1988-03-03
EP0197718A2 (en) 1986-10-15
KR860008202A (ko) 1986-11-12
PH29979A (en) 1996-10-29
FI861395A0 (fi) 1986-04-01
FI861395L (fi) 1986-10-06
CA1340825C (en) 1999-11-23
PT82342A (en) 1986-05-01
FI83966B (fi) 1991-06-14
DE3689384T3 (de) 2003-05-15
FR2579895A1 (enExample) 1986-10-10
IE860847L (en) 1986-10-05

Similar Documents

Publication Publication Date Title
CN85102921B (zh) 制备具有药物作用的透明质酸组份及含该组份的药物的方法
ATE412659T1 (de) Tubulysine, herstellungsverfahren und tubulysin- mittel
IE842596L (en) Hyaluronic acid derivatives
AU6669898A (en) Serine proteinase inhibitory activity by hydrophobic tetracycline
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
NO912410L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocyklen-derivater.
CN85108388B (zh) 一种祛痰剂的制备过程
BR0111264A (pt) Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização
HU9201258D0 (en) Process for the production of medical preparations for treating hiv infections and of their active agents
CN1003111B (zh) 胃肠外营养溶液
US20220387547A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
JP2006282586A (ja) 眼科用組成物
WO2018066963A1 (ko) 8-옥소-데옥시구아노신 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 각막 손상 치료용 약학적 조성물
WO2022154645A1 (ko) 히알루론산, 폴리에틸렌글리콜 및 실리콘 함유 성분을 포함하는 생체적합성 하이드로겔
KR100601810B1 (ko) 식작용 및 ｉｃａｍ-1 발현을 조절하기 위한 조성물 및 방법
LEOPOLD Local toxic effect of detergents on ocular structures
US6114383A (en) Drugs inhibiting progress of pterygium and postoperative recurrence of the same
EP0410749B1 (en) Anthocyanidins for the treatment of ophthalmic diseases
WO2021015588A1 (ko) 히알루론산 및 폴리에틸렌글리콜을 포함하는 생체적합성 하이드로겔
Margulies et al. Dendritic corneal lesions associated with soft contact lens wear
JPH06271478A (ja) ドライアイ治療剤
KR100399657B1 (ko) 혈관신생 억제제
Boxley et al. Contact dermatitis to one ingredient of Xerumenex ear drops.
WO1993006856A1 (en) Treating ophthalmic fibrosis using interferon-alpha
RU2068691C1 (ru) Средство для лечения вирусных заболеваний, вызванных вирусом герпеса

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C13 Decision
GR02 Examined patent application
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term